[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622398":3},{"organization":4,"outcomesModule":7,"designInfo":59,"detailedDescription":68,"studyPopulation":62,"armGroups":69,"interventions":82,"overallOfficials":93,"centralContacts":97,"locations":106,"responsibleParty":134,"collaborators":62,"id":137,"slug":62,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":62,"eligibilityCriteria":142,"healthyVolunteers":138,"sex":143,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":62,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":108,"whyStopped":62,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Northern Jiangsu People's Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"90-day mortality","All-cause mortality at day 90 after randomization","90 days after randomization",[14,18,22],{"measure":15,"description":16,"timeFrame":17},"28-day mortality","All-cause mortality at day 28 after randomization","28 days after randomization",{"measure":19,"description":20,"timeFrame":21},"ICU mortality","All-cause mortality at ICU discharge","From randomization to ICU discharge (up to 90 days)",{"measure":23,"description":24,"timeFrame":25},"Hospital mortality","All-cause mortality at hospital discharge","From randomization to hospital discharge (up to 90 days)",[27,31,34,37,41,44,47,50,53,56],{"measure":28,"description":29,"timeFrame":30},"Shock reversal time","Reversal of shock is defined as the maintenance of a systolic blood pressure of at least 90 mmHg without vasopressor support for at least 24 h. Time to shock reversal is defined as the time from randomization to shock reversal.","From randomization up to 28 days",{"measure":32,"description":33,"timeFrame":21},"ICU length of stay","Time in days until ICU discharge",{"measure":35,"description":36,"timeFrame":25},"Hospital length of stay","Time in days until hospital discharge",{"measure":38,"description":39,"timeFrame":40},"Change in Sequential Organ Failure Assessment (SOFA) score at 72 hours","The Sequential Organ Failure Assessment (SOFA) score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction and worse clinical outcomes. The change in SOFA score (ΔSOFA) is calculated as the SOFA score at enrollment minus the SOFA score at 72 hours after randomization. If a patient is discharged from the ICU within 72 hours, the SOFA score at ICU discharge will be used for analysis.","72 hours after randomization",{"measure":42,"description":43,"timeFrame":40},"72h lactate","lactate level at 72h after randomization",{"measure":45,"description":46,"timeFrame":40},"72h P\u002FF","P\u002FF at 72h after randomization",{"measure":48,"description":49,"timeFrame":17},"ICU-free days up to day 28","Total number of days alive and free of ICU stay during the 28 days after randomization.",{"measure":51,"description":52,"timeFrame":17},"Vasopressor-free days up to day 28","Total number of days alive and free of vasopressor during the 28 days after randomization.",{"measure":54,"description":55,"timeFrame":17},"Ventilator support-free days up to day 28","Total number of days alive and free of ventilator support during the 28 days after randomization.",{"measure":57,"description":58,"timeFrame":17},"CRRT-free days up to day 28","Total number of days alive and free of CRRT during the 28 days after randomization.",{"allocation":60,"interventionModel":61,"interventionModelDescription":62,"primaryPurpose":63,"observationalModel":62,"timePerspective":62,"maskingInfo":64},"RANDOMIZED","PARALLEL",null,"TREATMENT",{"masking":65,"maskingDescription":62,"whoMasked":66},"SINGLE",[67],"OUTCOMES_ASSESSOR","Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, and septic shock represents its most severe form, characterized by profound circulatory and metabolic abnormalities with high mortality.\n\nCurrent international guidelines recommend intravenous hydrocortisone as adjunctive therapy in patients with septic shock who remain hypotensive despite adequate fluid resuscitation and vasopressor treatment. However, critically ill patients may exhibit relative deficiencies of both glucocorticoid and mineralocorticoid activity, and hydrocortisone alone may not fully meet the physiological demands under severe stress. In recent years, combination therapy with hydrocortisone and fludrocortisone has been investigated, but published trials have reported inconsistent results regarding mortality, shock reversal, and adverse events.\n\nTherefore, this randomized controlled trial aims to evaluate the efficacy and safety of hydrocortisone combined with fludrocortisone, compared with standard therapy, in patients with septic shock.",[70,76],{"label":71,"type":72,"description":73,"interventionNames":74},"Hydrocortisone plus Fludrocortisone","EXPERIMENTAL","Hydrocortisone: 200 mg per day administered by continuous intravenous infusion for up to 7 days or until ICU discharge, whichever occurs first.\n\nFludrocortisone: 50 μg administered orally or via nasogastric tube once daily for up to 7 days or until ICU discharge, whichever occurs first.",[75],"Drug: Hydrocortisone plus Fludrocortisone",{"label":77,"type":78,"description":79,"interventionNames":80},"Standard care","ACTIVE_COMPARATOR","Patients will receive standard care for septic shock according to current international guidelines, including fluid resuscitation, vasopressor therapy, antimicrobial treatment, and other supportive measures, including the use of hydrocortisone at the discretion of the treating physician, but without fludrocortisone.",[81],"Other: Standard care",[83,90],{"type":84,"name":71,"description":85,"armGroupLabels":86,"otherNames":87},"DRUG","Hydrocortisone will be administered at a dose of 200 mg per day by continuous intravenous infusion.\n\nFludrocortisone will be administered at a dose of 50 μg once daily orally or via nasogastric tube.\n\nBoth drugs will be given for up to 7 days or until ICU discharge, whichever occurs first.",[71],[88,89],"Hydrocortisone Injection","Fludrocortisone Acetate Tablets",{"type":6,"name":77,"description":91,"armGroupLabels":92,"otherNames":62},"Patients will receive standard care for septic shock according to current international and institutional guidelines, including fluid resuscitation, vasopressor therapy, antimicrobial treatment, and other supportive measures. Fludrocortisone will not be administered.Hydrocortisone may be administered at the discretion of the treating physician.",[77],[94],{"name":95,"affiliation":5,"role":96},"Qingquan Lyu, Master","PRINCIPAL_INVESTIGATOR",[98,102],{"name":95,"role":99,"phone":100,"phoneExt":62,"email":101},"CONTACT","0086-18051063899","bonhomie2014@163.com",{"name":103,"role":99,"phone":104,"phoneExt":62,"email":105},"Xiaohua Gu, Master","0086-18051062325","njguxiaohua@163.com",[107],{"facility":5,"status":108,"city":109,"state":110,"zip":111,"country":112,"countryCode":113,"cosmosGeoPoint":114,"geoPoint":119,"contacts":120},"RECRUITING","Yangzhou","Jiangsu","225000","China","CN",{"type":115,"coordinates":116},"Point",[117,118],119.43583,32.39722,{"lat":118,"lon":117},[121,122,123,124,126,128,130,132],{"name":95,"role":99,"phone":100,"phoneExt":62,"email":101},{"name":103,"role":99,"phone":104,"phoneExt":62,"email":105},{"name":95,"role":96,"phone":62,"phoneExt":62,"email":62},{"name":103,"role":125,"phone":62,"phoneExt":62,"email":62},"SUB_INVESTIGATOR",{"name":127,"role":125,"phone":62,"phoneExt":62,"email":62},"Ruiqiang Zheng, Bachelor",{"name":129,"role":125,"phone":62,"phoneExt":62,"email":62},"Jiangquan Yu, Doctor",{"name":131,"role":125,"phone":62,"phoneExt":62,"email":62},"Ying Shi, Master",{"name":133,"role":125,"phone":62,"phoneExt":62,"email":62},"Yuanjin Pan, Bachelor",{"type":96,"investigatorFullName":135,"investigatorTitle":136,"investigatorAffiliation":5,"oldNameTitle":62,"oldOrganization":62},"Qing-quan Lv","Principal Investigator","100622398",false,"NCT07383103","Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock","Initiation of Hydrocortisone and Fludrocortisone in Adult Patients With Septic Shock：A Prospective Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n(1)18≤Age≤90; (2)Diagnosis of septic shock within 12 h.\n\nExclusion Criteria:\n\nPatients meeting any of the following conditions will be excluded:\n\n1. Systemic corticosteroid therapy within the last 3 months before septic shock;\n2. High-dose steroid therapy;\n3. Immunosuppression;\n4. Pregnant;\n5. Known allergy to hydrocortisone or fludrocortisone;\n6. Presence of gastrointestinal bleeding, perforation, or other conditions requiring fasting;\n7. Anticipated death from a preexisting disease within 90 days after randomization (as determined by the enrolling physician);\n8. Refusal of the attending staff or patient family;\n9. Current participation in another clinical trial.","ALL","18 Years","90 Years",{"count":147,"type":148},336,"ESTIMATED","INTERVENTIONAL",[151],"PHASE4","The purpose of this study is to evaluate the efficacy and safety of the combination therapy of hydrocortisone and fludrocortisone among adult patients with septic shock.",[154],"Septic Shock",[156,157,158,159],"septic shock","hydrocortisone","fludrocortisone","mortality","2026-03-03",{"date":162,"type":163},"2026-03-04","ACTUAL",{"date":165,"type":163},"2026-03-02",{"date":167,"type":148},"2028-12-31",{"name":5,"class":6},1]